Abstract:Objective To observe the effect of recombinant human endostatin (endostar) in combination with radiation on hepatic carcinoma xenografts in mice under different timing of administration, endostar dose and radiation dose.Methods (1) The xenotransplanted tumor model of human hepatic carcinoma in mice was established.The mice were randomly grouped based on timing of administration, endostar dose and radiation dose, with 10 mice in each group.The length and diameter of xenografts were measured every other day.The tumor suppress effect was compared between early administration and late administration manners.(2) The mice were divided into 6 groups with 30 mice in each group and treated in early administration manner.Then the overall survival was observed.(3) MTT assay was used to observe the synergistic effect influenced by the dose of endostar and radiation.(4) Western blotting was used to detect the expression of epidermal growth factor (EGF) and vascular endothelial growth factor receptor-1(Flt-1) in early and late administration manners.(5) Immunochemistry was used to test the expression of vascular endothelial growth factor (VEGF) and KDR, as well as microvascular density of hepatic carcinoma xenografts.(6) Cyto-apoptosis was observed by electron microscope and cell cycles and apoptotic rates were determined by flow cytometry.Results Compared with control group, endostar could suppress the growth of hepatic carcinoma xenografts (P<0.05), and early administration manner performed better than late administration manner (P<0.05).Synergistic effect was found in 8 mg/kg endostar+RT group of early administration manner, and the tumor suppress rate was 58.0%, better than other groups (P<0.05).The median overall survival of 8 mg/kg endostar+RT group was 55.6 days with the life prolonging rate of 29.3%, better than other groups (P<0.05).5 μg/ml endostar in combination with 4Gy radiation on HUVECs cells showed synergistic effect with the proliferative inhibition rate of 59.20%, better than other doses of endostar (P<0.05).200 μg/ml endostar in combination with 4 Gy radiation on HepG2 cells showed synergistic effect with the proliferative inhibition rate of 43.45%, better than other doses of endostar (P<0.05).5 μg/ml endostar in combination with different doses of radiation on HUVECs, as well as 200 μg/ml endostar in combination with different doses of radiation on HepG2 cells both showed better proliferative inhibition rates than using endostar or radiation alone (P<0.05).Western blotting test showed that the expressions of EGF in 8 mg/kg endostar group and 8 mg/kg endostar+RT group of early administration manner was lower than those of late administration manner.However, the expression of Flt-1 between the two manners had no difference (P>0.05).Endostar in combination with radiation could significantly decrease MVD of hepatic carcinoma xenografts, the MVD in 8 mg/kg endostar+RT group was 8.6±1.3, lower than other groups (P<0.05).In 8 mg/kg endostar+RT group, the expression of VEGF and KDR was lower than other groups (P<0.05).Apoptoic changes were observed under lectron microscope in endostar in combination with radiation groups.Flow cytometry showed that cell cycles were blocked in S phase in 8 mg/kg endostar+RT group, and the cyto-apoptotic rate was higher than other groups (P<0.05).Conclusion The synergistic effect of endostar in combination with radiation is correlated to timing of administration, endostar dose and radiation dose, and the effect of early administration of endostar is superior to the late.

Recombinant Human Endostatin Regulates Proliferation and Related Protein Expression in Human Multiple Myeloma Cell Line RPMI 8226

Construction of pcDNA3-Endo eukaryon expression plasmid and angiogenesis inhibition in vitro

Radiosensitization of Recombinant Human Endostatin in Human Lung Squamous Cancer Cells in Vitro

Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice

Inhibitory Effect of Endostatin Expressed by Human Liver Carcinoma SMMC7721 on Endothelial Cell Proliferation in Vitro.

[Preliminary Study on the Anti-Leukemia Effect of Recombinant Human Endostatin].

STUDY OF ANTI-TUMOR EFFECT OF RECOMBINANT HUMAN ENDOSTATIN

Endostar, a Modified Recombinant Human Endostatin, Suppresses Angiogenesis through Inhibition of Wnt/β-Catenin Signaling Pathway

Retrovirus-mediated Gene Transfer of Human Endostatin Inhibits Growth of Human Liver Carcinoma Cells SMMC7721 in Nude Mice

Antimyeloma Effect of Recombinant Human Endostatin in Vitro

EP regimen combined with recombinant human vascular endostatin (Endostar) inhibits the proliferation of small-cell lung cancer cell Line NCI-H446 and promotes the apoptosis

Endostar inhibits hypoxia-induced cell proliferation and migration via the hypoxia-inducible factor-1α/vascular endothelial growth factor pathway in vitro.

Endostar, a recently introduced recombinant human endostatin, inhibits proliferation and migration through regulating growth factors, adhesion factors and inflammatory mediators in choroid-retinal endothelial cells

Inhibitory Effects of Lung Squamous Cell Carcinoma in Vitro by Endostar

Therapeutic Efficacy of Recombinant Human Endostatin Combined with Chemotherapeutics in Mice-Transplanted Tumors

Enhanced Inhibitory Effects of Recombinant Human Endostatin Combined with Dacarbazine on Melanoma and Their Action Mechanism

Inhibitory effect of endostatin mediated by retroviral gene transfer on human liver carcinoma SMMC 7721 in vivo

Changes And Significance Of Lymphocyte Subsets In Patients With Advanced Nsclc Before And After Endostar Combined Chemotherapy

The dose and time factors on synergistic effects of the combination of endostar and radiation against hepatic carcinoma xenografts in mice

Study on apoptosis and its mechanism of endostatin in endometrial carcinoma HEC1B cells

Endostar Rebuilding Vascular Homeostasis and Enhancing Chemotherapy Efficacy in Cervical Cancer Treatment